Close Menu

NanoString

The evaluation presented at SABCS last week highlighted the importance of considering node-positive and -negative patients, and incorporating clinical information with molecular tests. 

Merck is hoping NanoString's multiplex platform can support gene expression signatures that will better predict which patients will respond to checkpoint inhibitors like its Keytruda.

The Seattle-based firm is working with Oregon Health & Science University researcher Lisa Coussens on a tool for studying the innate immune system in oncology.

The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.

Agendia is launching a patient access program to position MammaPrint in clinics, while other test makers are taking a wait-and-see approach.

The molecular analysis firm saw instrument sales rise 62 percent, and announced plans for a new digital spatial profiling instrument.

The researchers will use genomics to address challenges facing Canada's forestry, healthcare, agricultural, and aquacultural industries.

The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.

Coming off a nearly 9 percent rise in July, the GenomeWeb Index fell more than 2 percent in August, mimicking the Nasdaq Biotechnology Index, which fell 3 percent.

The gene expression assay, which targets 18 markers, is being used by Merck in three new Phase III clinical trials to expand the indication for Keytruda.

Pages

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.